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ing to the CONAPO’s Mexican population projection with 40 years old or over, the 
prevalence of the COPD in Mexico (PLATINO study) and the proportion of people 
that uses biomass for cooking. A deterministic sensitivity analysis was performed 
in both cases. Results: Annual cost of glycopyrronium bromide monotherapy was 
US$265.27 and for tiotropium bromide monotherapy was US$242.30 in one year 
horizon with a percent difference of 10.16% per patient. The budget impact costs 
in the first year were $287,409,746.74 and $262,527,500.25 for tiotropium bromide 
monotherapy and glycopyrronium bromide monotherapy respectively, with savings of 
9.5% using glycopyrronium bromide monotherapy. ConClusions: Glycopyrronium 
bromide monotherapy is less costly than tiotropium bromide monotherapy which 
shows us that is possible to achieve cost-savings with at least the same clinical ben-
efit from the perspective of the Mexican public health system, in specific from IMSS. 
*IMSS (Mexican Institute of Social Security) *CONAPO (National Council of Population) 
*Exchage rate 14.55 MXN
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objeCtives: To estimate annual loss of productivity costs attributable to being over-
weight or having obesity in working US adults with asthma patients. Methods: This 
study applied a cross-sectional design using the 2008-2012 Medical Expenditure Panel 
Survey (MEPS). Asthma patients (18-64 years old) were identified by self-reported 
diagnosis, Clinical Classification Codes of 128, or ICD-9-CM code of 493. To investigate 
the impact of being overweight or having obesity, patients were classified as normal-
weight (18.5≤ BMI< 25), overweight (25≤ BMI< 30), and obese (BMI≥ 30). Productivity 
loss costs, which were measured based on missed work days due to illness or injury 
for one year and the hourly wage, were estimated using a two-part model to adjust 
for patients with zero costs. To estimate the productivity loss costs attributable to 
being overweight or obese, each group of costs was estimated by assuming every-
body is overweight or obese; these costs were then re-estimated by assuming eve-
rybody was normal, and the mean difference between the two estimated costs was 
calculated. All costs were converted to 2013 US dollars using the Consumer Price 
Index (CPI). Results: Among a total of 5,391 working adults with asthma, preva-
lence of normal-weight was 28.9%, overweight 31.4%, and obese 39.7%. Annual aver-
age productivity loss costs for normal, overweight, and obesity in asthma patients 
were $360(95%CI:$297-$423), $461(95%CI:$374-$548), and $753(95%CI:$620-$886) per 
patient, respectively. Among patients with asthma who had loss of productivity costs, 
those with obesity had 1.33 times greater productivity loss costs than normal-weight 
patients. Thus, the productivity loss costs attributable to being overweight or obesity 
in working asthma patients were estimated at $24(95%CI:$24-$25) or $190(95%CI:$184-
$196) per patient per year, respectively. ConClusions: The loss of productivity costs 
among US asthma patients is substantial, which is only further amplified by the 
presence of obesity. This study highlights the importance of obesity control in order 
to reduce burden of asthma treatment and enhance productivity.
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objeCtives: Chronic urticaria (or chronic hives) can be inducible or spontaneous 
(CSU). Data supporting the impact of CSU on patients and comparisons with other 
dermatological diseases are scarce. This study evaluated economic burden associated 
with CSU relative to psoriasis (PsO) among the adults in 5 European (5EU) countries 
and United States (US). Methods: Data from diagnosed chronic hives (used as proxy 
for CSU) and PsO patients collected in the National Health and Wellness Survey (2010-
11 & 2013) for 5EU and (2010-12) for US were used for this retrospective, cross-sectional 
analysis. Outcome measures included the Work Productivity and Activity Impairment 
questionnaire (WPAI) and self-reported healthcare use in prior 6 months. Bivariate 
analysis (t-tests for continuous and chi-square for categorical variables) was used to 
compare patients with CSU vs. PsO. Results: Study included 1,516 patients with CSU 
(769 EU; 747 US) and 12,964 patients with PsO (7,857 EU; 5,107 US). In EU, employed 
CSU patients reported higher absenteeism (10.5% vs. 6.8%), presenteeism (27.4% vs. 
20.5%), overall work impairment (32.6% vs. 24.6%) and activity impairment (39.5% vs. 
30.5%) compared to PsO patients. Similarly, US CSU patients reported higher WPAI 
parameters (8.6% vs. 4.6%), (25.6% vs. 19.1%), (28.9% vs. 21.4%) and (38.9% vs. 31.2%), 
respectively (p< 0.01 for all). CSU patients had more hospitalizations (0.43 vs. 0.17), 
and more visits to ER (0.75 vs. 0.25), physician (3.08 vs. 2.52) and allergist (0.21 vs. 0.06) 
compared to PsO patients (p< 0.001 for all) in EU. Similarly, US CSU patients showed 
more hospitalizations (0.26 vs. 0.15), ER visits (0.42 vs. 0.25), physician (1.46 vs. 1.24) 
and allergist (0.25 vs. 0.09) visits than PsO patients (p< 0.05 for all). ConClusions: 
This analysis of patient reported data show that CSU has a similar or even higher 
economic burden than PsO patients in both EU and US patient population.
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patients. As the results were mainly driven by the lower rates of severe exacerbations 
in the tio arm, this highlights the importance of exacerbations when assessing cost-
effectiveness in moderate to very severe COPD. Overall, a broader range of evidence 
parameters should be considered in economic modelling of COPD.
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objeCtives: Patients with severe refractory asthma experience persistent symptoms 
despite adhering to guideline-based therapies, and they utilize a disproportionate 
share of asthma healthcare resources. Several new treatments are available that 
have been shown to improve symptoms and quality of life in patients with refrac-
tory asthma. The objective of this study was to determine the cost effectiveness of 
primary medical treatment strategies for severe refractory asthma, including biologic 
therapies and follow-on bronchial thermoplasty. Methods: A decision tree analytic 
model to investigate the comparative effect of two biologic therapies and follow-on 
bronchial thermoplasty on asthma exacerbation-related costs and utilities. Endpoints 
of interest were ER visits, hospitalizations, death, and direct healthcare costs. Base-
case inputs were taken from prior literature or assumed as necessary. We used a 
U.S. healthcare perspective, a hypothetical cohort of 10,000 adult refractory asthma 
patients, an annual cycle, and 10-year time horizon to construct our model. Results: 
Among patients who respond to biologic treatment, the addition of bronchial thermo-
plasty was not cost-effective. Mepolizumab without bronchial thermoplasty was the 
most cost-effective option for biologics responders, with a 10-year-per-patient cost of 
$116,776 and 5.46 QALYs gained (ICER $21,388). Among patients who do not respond 
to biologic treatment, bronchial thermoplasty is a cost effective treatment option 
($33,161/QALY). Sensitivity analysis shows that the model is reactive to changes in 
medication cost; a 10% increase in mepolizumab cost results in only omalizumab 
alone or with bronchial thermoplasty being cost-effective. ConClusions: In a 
hypothetical cohort of refractory asthma patients over a 10-year period, it is not cost 
effective to add bronchial thermoplasty to biologic responders’ therapy; however, in 
biologic non-responders, bronchial thermoplasty remains a cost effective add-on 
treatment option. Future studies should incorporate long-term efficacy inputs of 
bronchial thermoplasty and real-world mepolizumab cost data to address assump-
tions necessary due to limited data currently availability for these newer therapies.
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bACKGRounds: Smoking cessation medications have been shown to yield higher 
success rates and sustained abstinence when compared to unassisted quit attempts. 
Although unassisted smoking cessation is still common in Japan, various treat-
ments, including nicotine replacement therapy (NRT) and varenicline, can be 
covered by the health insurance system. objeCtives: To compare the health and 
economic consequences in Japan of using pharmacotherapy to support smoking ces-
sation with unassisted attempts and the current mix of strategies used. Methods: 
A discrete event simulation model was developed, which included multiple quit 
attempts and relapses. The risk of developing smoking-related diseases was esti-
mated based on the duration of smoking abstinence. Data collected from a survey 
conducted in Japan was used to determine the interventions selected by smokers 
initiating a quit attempt, along with the time between multiple quit attempts. The 
analyses were conducted from healthcare payers’ perspective, with supplemental 
analyses in which productivity losses due to smoking-related diseases were esti-
mated. Time horizon was set to lifetime. Results: Using pharmacotherapy (NRT 
or varenicline) to support quit attempts proved to be dominant when compared 
with unassisted attempts or the current mix of strategies (most are unassisted). If 
varenicline is always chosen as the first choice for a quit attempt, it would save JPY 
206,100 and prolong 0.08QALY per smoker over a lifetime horizon, compared to cur-
rent mix of strategies. The greatest cost saving was observed for the smokers aged 
from 40 to < 50 years. ConClusions: Increased utilization of smoking cessation 
pharmacotherapy to support quit attempts is estimated to be cost-saving, as well 
as to improve health outcomes of the many smokers who want to quit.
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objeCtives: To perform a cost-minimization analysis and budget impact of gly-
copyrronium bromide monotherapy versus tiotropium bromide monotherapy as a 
maintenance treatment in adult patients with moderate to severe chronic obstructive 
pulmonary disease (COPD) from the perspective of the Mexican public healthcare 
system. Methods: Using data from GLOW 5 study, it was established the equiva-
lence of safety and efficacy of glycopyrronium bromide monotherapy and tiotropium 
bromide monotherapy, so it is evaluated the annual costs of each therapy to establish 
the cost-savings with glycopyrronium bromide monotherapy. COPD drug cost was 
estimated for one year in the cost-minimization analysis, using local prices for public 
healthcare institutions (IMSS). It was developed a 5 year horizon budget impact from 
the perspective of the Mexican public healthcare system with an annual discount 
rate of 5%. The total population used for the budget impact was calculated accord-
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summaries of their data, the ability to track their progress through a questionnaire, 
and “thank you” messages for completing frequent questionnaires. Patients would 
be motivated to complete a daily dairy by seeing their overall percent compliance to 
date. Investigators should consider including these types of elements when design-
ing ePRO assessments for clinical trials.
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objeCtives: Chronic spontaneous/idiopathic urticaria (CSU/CIU) is defined as the 
spontaneous appearance of itchy hives, angioedema, or both lasting ≥ 6 weeks. CSU/
CIU has a significant yet underestimated socioeconomic impact. The ASSURE-CSU 
study aims to identify and quantify the humanistic and economic burden of CSU/
CIU. Here we present Canadian specific data on utility values. Methods: The study 
included a retrospective medical record abstraction, a cross-sectional PRO survey, 
and 7day diary of patients with CSU/CIU still symptomatic despite treatment, aged 
≥ 18 years, with disease persisting for ≥ 12 months. Patients completed the weekly 
Urticaria Activity Score (UAS7) and the EQ-5D-3L, a 2-part instrument comprised of 
the EQ-5D and the Visual Analog Scale (VAS). ED-5D-3L and VAS utility values were 
derived using a Canadian-specific scoring algorithm and a standard UK algorithm, 
respectively. Descriptive statistics were provided for these variables and stratified 
by disease severity. Results: The cohort included 99 patients with demographics 
in line with published characteristics of CSU/CIU patients and distributed across 
severity levels. The instrument was completed by 86 patients. Overall, the mean (SD) 
EQ-5D utility score was 0.7 (0.30); while the mean (SD) VAS utility score was 71.4 
(19.24). The dimensions of the EQ-5D-3L most affected where pain/discomfort and 
anxiety/depression with 61.4% and 40.9% of patients reporting moderate to extreme 
problems, respectively. Utility values decreased with increased disease severity for 
overall and dimension specific scores for both tools. ConClusions: Compared to 
the average utility score of an average Canadian population (0.875), the results of 
this study at 0.7 demonstrate that CSU/CIU has a significant impact on patients’ 
health status and quality of life; with patients suffering from moderate to severe 
urticaria showing a greater impact on patients’ health state.
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objeCtives: To assess the impact of pharmacists-led non-clinical interventions on 
knowledge, attitude and perception among pulmonary tuberculosis (PTB) patients 
in Pakistan. Methods: A randomized controlled non-clinical trial was piloted on 
PTB patients under the supervision of registered pharmacists whereby PTB patients 
received educational non-clinical interventions regarding knowledge, attitude and 
perception on PTB. Self-administered research tool was used and demographic 
characteristics of the patients were determined by means of descriptive statistics. 
Data was analyzed by using SPSS 21.0. Comparison between trial group and con-
trol group was done with the help of inferential statistics. Results: Two hundred 
and eighty PTB patients were randomly chosen for the study i.e. one hundred and 
forty in each group. No significant differences were observed in either group for 
mean age, gender, education level, occupation and income whereas a significant 
improvement (p< 0.001) in the knowledge, attitude and perception was noted in the 
interventional group. ConClusions: The pharmacist-led, non-clinical interven-
tion caused a significant improvement in PTB patients’ knowledge, attitude and 
perception scores. This study highlights pharmacists’ need and their significantly 
important role towards better patient care and education. These finding are con-
siderably useful for better disease management and control.
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objeCtives: The purpose of this study was to examine the treatment outcomes of 
smear positive pulmonary TB cases registered in TB patients in Quetta. Methods: 
Cross sectional retrospective cohort study was performed on TB patient in Fatima 
Jinnah chest hospital, Quetta. Retrospective medical records of smear-positive 
tuberculosis patients registered in first quarter of year 2012. Tuberculosis treatment 
outcomes were assessed according to WHO guidelines. The descriptive statistics 
was used to present the demographic and disease related information. Inferential 
statistics was used to the evaluation relationship among study variables. All anal-
yses were performed using SPSS 20.0. Results: Out of the 131 TB patients (67 
males and 64 females). Majority of the patients were in the age group 18-47 (73.7%). 
High percentage of the patients had successful treatment with treatment outcome 
“Completed” and ‟cured” were 65.5% (n= 74), whereas, death occurred in only 5.3% 
(n= 7) of patients. Demographic characteristics age was the only determine factor 
objeCtives: Chronic spontaneous/idiopathic urticaria (CSU/CIU) is defined as the 
spontaneous appearance of itchy hives, angioedema, or both lasting ≥ 6 weeks. CSU/
CIU has a significant yet underestimated impact on patient’s work productivity. The 
ASSURE-CSU study aims to identify and quantify the humanistic and economic 
burden of CSU/CIU. Here we present Canadian data on work productivity and indi-
rect costs. Methods: Patients with CSU/CIU, aged ≥ 18 years, with disease for ≥ 12 
months, symptomatic despite treatment were recruited in the study. Data were col-
lected on absenteeism and productivity loss via the Work Productivity and Activity 
Impairment –Specific Health problem (WPAI-SHP) questionnaire. The associated 
indirectly monthly costs were estimated based on 150hr/working week and average 
wage $CAD 25.62/hr. Descriptive statistics were provided and stratified by disease 
severity. Results: Cohort included 99 patients with a mean age of 50.8 years; 5 years 
mean disease duration, and a higher proportion of women (77.8%). Overall, 86 patients 
completed the WPAI with 54.7% employed (assessed separately from the WPAI, 46.5% 
had full-time employment). In the last 7 days, the mean proportion of time missed at 
work due to CSU/CIU was 6.0% (SD= 12.0%). The greatest percentage of time missed 
due to CSU/CIU was reported in moderate and severe patients (8.9% and 10.6%, respec-
tively). The mean proportion of overall work impairment due to CIU/CSU was 30.6% 
(SD= 27%). Total indirect monthly cost of work productivity loss was estimated to be 
a mean (SD) of $1,177 per patient in full-time employment. The overall indirect costs 
increased with disease severity. ConClusions: This Canadian-specific analysis from 
ASSURE-CSU suggests that almost all patients in employment are affected at work by 
their disease, either through absenteeism or reduced productivity at work resulting 
in significant economic impact for employers and society.
PRS32
coSt-conSequence of eoSinoPhiLic ASthmA Among PAtientS tReAted 
AccoRding to eRS/AtS guideLineS
Casciano J.1, Krishnan J.2, Buatti-Small M.3, Li C.4, Dotiwala Z.1
1eMAX Health Systems LLC., White Plains, NY, USA, 2University of Illinois Hospital and Health 
Sciences System, Chicago, IL, USA, 3Teva, Frazer, PA, USA, 4University of Arkansas for Medical 
Sciences, Little Rock, AR, USA
objeCtives: Compare healthcare resource utilization of patients with severe 
asthma and elevated blood eosinophils (EOS) versus normal EOS. Methods: 
Asthma patients were extracted from EMRClaims+ database from Jan 2004-July 
2011. Date of asthma diagnosis was defined as the index date. The 12-month 
period following index was defined as ‘assessment’ period, with disease severity 
classified by factors such as medication use and lung function based on the newly 
published European Respiratory Society/American Thoracic Society guidelines. 
Patients with ‘severe’ asthma were classified as those with ‘elevated’ (≥ 400 cells/
µL) and ‘normal’ EOS (< 400 cells/µL). Patients were followed for a maximum 
period of 12 months after index to record all-cause hospitalizations, ER and out-
patient visits and associated costs. Mean hospitalizations, visits, and costs were 
compared using Wilcoxon signed rank test. Proportions were compared using Chi 
square tests. Logistic regression was conducted to assess the influence of elevated 
EOS on probability of incurring resource use after controlling for demographics 
and baseline comorbidities. Results: Of the 2,164 asthma patients identified, 
184 (9%) were concordant with guideline recommendation for medication use for 
severe asthma (Guideline-Concordant-Severe: GCS patients). Of these, 56 (30%) 
had elevated EOS. A significantly greater proportion of GCS patients with elevated 
EOS had admissions during follow-up compared to those with normal EOS (29% 
vs 13%, p= 0.013). GCS patients with elevated EOS had significantly greater mean 
monthly admissions compared to normal EOS patients (0.1 vs 0.02, p= 0.011) and 
8 times the hospitalization cost compared to the group with normal EOS [$834 
(SD:4403) vs. $106 (SD:336), p= 0.012]. Logistic regression showed that patients 
with elevated EOS had greater likelihood of admissions during follow-up (OR: 2.61, 
p= .033). ConClusions: Among patients with severe asthma with treatments 
concordant with ERS/ATS guidelines, those with elevated EOS experienced more 
frequent hospital admissions and greater cost compared to those with normal EOS.
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objeCtives: Clinical trials for COPD are increasingly using electronic methods 
to collect patient-reported outcomes (ePRO). As use of this technology increases, 
it is important to consider patient preference in questionnaire design. This study 
examined patient preference for receiving real-time feedback while completing 
ePRO assessments. Methods: A total of 103 patients with COPD were surveyed. 
Patients were asked to assume that they were using a handheld or tablet device to 
complete questionnaires as part of a clinical trial; they were then presented with 
example screens and asked about types of feedback they might receive on the 
device. Results: Patients ranged in age from 32 to 86 years and were 55% female. 
50% reported previous participation in a clinical trial. 59% reported that they would 
like to see a “thank you” screen at the end of each questionnaire. 81% thought 
it would be helpful or necessary to regularly receive a graph summarizing their 
responses. 81% preferred to see their progress as they completed a questionnaire; of 
these, 41% preferred a progress bar and “Question X of X” message and 47% preferred 
just the progress bar. 69% said they would like the first screen to summarize the 
questionnaire’s length and estimated completion time. Regarding feedback about 
daily diary compliance, 76% reported that a summary screen showing their percent 
compliance would motivate them to complete their diary each day. ConClusions: 
Patients with COPD prefer to receive real-time feedback while completing ePRO 
assessments, and are motivated by compliance information. Specifically, they prefer 
